Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC012F in Transplant In-Eligible Newly Diagnosed Multiple Myeloma
NCT05840107Phase 1Recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- May 2023
- Primary completion
- Sep 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GC012 in multiple myeloma (MM), sponsored by Shanghai Changzheng Hospital. Primary endpoints: Adverse Events (AE) after CAR-T infusion at 1 year, Percentage of patients with complete response (CR) and stringent complete response (sCR) at 2 years and 4 more. Started May 2023; status: recruiting.
02
Drugs
GC012
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05840107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05840107.